1. |
Cunba BA. Nosocomial pneumonia. Diagnostic and therapeutic considerations. Med Clin North Am, 2001, 85: 79-114.
|
2. |
Depuydt P, Myny D, Blot S. Nosocomial pneumonia: aetiology,diagnosis and treatment. Curr Opin Pulm Med, 2006, 12: 192-197.
|
3. |
Cunha BA. Antibiotic selection is crucical of optimal empiric monotherapy of ventilator-associated pneumonia. Crit Care Med, 2007, 35:1992-1994.
|
4. |
Rello J. Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia. Eur Respir Rev, 2007, 16: 33-39.
|
5. |
黎毅敏, 黃紅川, 劉曉青, 等. 重癥監護病房銅綠假單胞菌醫院獲得性感染暴發的流行病學調查. 中國呼吸與危重監護雜志,2006, 5: 413-417.
|
6. |
Schmitt DV, Leitner E, Welte T, et al. Piperacillin /Tazobactam vs Imipnenem/ cilaslatin in the treatment of nosocomial pneumonia-a double blind prospective multicentre study. Infection, 2006, 34 :127 -134.
|
7. |
Yong M, Plosker GL. Piperacillin/ tazobactam: a pharmacoeconomic review of its use in moderate to severe bactierial infections. Pharmacoeconomics, 2001, 19: 1135-1175.
|
8. |
American Thoracic Society; Infections Diseases Society of America.Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Am J RespirCrit Care Med, 2005, 171: 388-416.
|